1. Inebilizumab showed promise in improving function and reducing disease severity in patients with generalized myasthenia gravis.
2. Participants receiving inebilizumab demonstrated greater improvement in MG-ADL scores at 26 weeks compared with placebo.
3. The trial emphasized the potential efficacy of targeting CD19+ B cells in depleting antibody-secreting cells.
4. Inebilizumab was found to have a significant safety profile, with some adverse events reported. 
5. Further data are essential to confirm the long-term safety and efficacy of inebilizumab, as highlighted by the researchers.
6. MINT was a phase III trial involving 238 participants with generalized myasthenia gravis from 18 countries, focusing on the efficacy of inebilizumab in improving patient outcomes.

Source: New England Journal of Medicine